TULLIS DICKERSON CAPITAL FOCUS III L.P. 13D and 13G filings for Exagen Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-02-13 06:13 am Purchase | 2023-12-31 | 13G | Exagen Inc. XGN | TULLIS DICKERSON CAPITAL FOCUS III L.P. | 1,867,116 10.700% | 9,167 (+0.49%) | Filing |
| 2023-02-07 12:54 pm Sale | 2022-12-31 | 13G | Exagen Inc. XGN | TULLIS DICKERSON CAPITAL FOCUS III L.P. | 1,857,949 11.380% | -10,190 (-0.55%) | Filing |
| 2022-02-14 1:10 pm Sale | 2021-12-31 | 13G | Exagen Inc. XGN | TULLIS DICKERSON CAPITAL FOCUS III L.P. | 1,868,139 11.560% | -22,383 (-1.18%) | Filing |
| 2021-02-16 06:21 am Sale | 2020-12-31 | 13G | Exagen Inc. XGN | TULLIS DICKERSON CAPITAL FOCUS III L.P. | 1,890,522 14.600% | -243,584 (-11.41%) | Filing |
| 2020-02-14 4:09 pm Purchase | 2019-12-31 | 13G | Exagen Inc. XGN | TULLIS DICKERSON CAPITAL FOCUS III L.P. | 2,134,106 17.000% | 2,134,106 (New Position) | Filing |